https://scholars.lib.ntu.edu.tw/handle/123456789/580076
標題: | Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial | 作者: | Kudo M. Finn R.S. Qin S. Han K.-H. Ikeda K. Piscaglia F. Baron A. Park J.-W. Han G. Jassem J. Blanc J.F. Vogel A. Komov D. Evans T.R.J. Lopez C. Dutcus C. Guo M. Saito K. Kraljevic S. Tamai T. Ren M. ANN-LII CHENG |
公開日期: | 2018 | 出版社: | Lancet Publishing Group | 卷: | 391 | 期: | 10126 | 起(迄)頁: | 1163-1173 | 來源出版物: | The Lancet | 摘要: | Background: In a phase 2 trial, lenvatinib, an inhibitor of VEGF receptors 1–3, FGF receptors 1–4, PDGF receptor α RET, and KIT, showed activity in hepatocellular carcinoma. We aimed to compare overall survival in patients treated with lenvatinib versus sorafenib as a first-line treatment for unresectable hepatocellular carcinoma. Methods: This was an open-label, phase 3, multicentre, non-inferiority trial that recruited patients with unresectable hepatocellular carcinoma, who had not received treatment for advanced disease, at 154 sites in 20 countries throughout the Asia-Pacific, European, and North American regions. Patients were randomly assigned (1:1) via an interactive voice–web response system—with region; macroscopic portal vein invasion, extrahepatic spread, or both; Eastern Cooperative Oncology Group performance status; and bodyweight as stratification factors—to receive oral lenvatinib (12 mg/day for bodyweight ?60 kg or 8 mg/day for bodyweight <60 kg) or sorafenib 400 mg twice-daily in 28-day cycles. The primary endpoint was overall survival, measured from the date of randomisation until the date of death from any cause. The efficacy analysis followed the intention-to-treat principle, and only patients who received treatment were included in the safety analysis. The non-inferiority margin was set at 1·08. The trial is registered with ClinicalTrials.gov, number NCT01761266. Findings: Between March 1, 2013 and July 30, 2015, 1492 patients were recruited. 954 eligible patients were randomly assigned to lenvatinib (n=478) or sorafenib (n=476). Median survival time for lenvatinib of 13·6 months (95% CI 12·1–14·9) was non-inferior to sorafenib (12·3 months, 10·4–13·9; hazard ratio 0·92, 95% CI 0·79–1·06), meeting criteria for non-inferiority. The most common any-grade adverse events were hypertension (201 [42%]), diarrhoea (184 [39%]), decreased appetite (162 [34%]), and decreased weight (147 [31%]) for lenvatinib, and palmar-plantar erythrodysaesthesia (249 [52%]), diarrhoea (220 [46%]), hypertension (144 [30%]), and decreased appetite (127 [27%]) for sorafenib. Interpretation: Lenvatinib was non-inferior to sorafenib in overall survival in untreated advanced hepatocellular carcinoma. The safety and tolerability profiles of lenvatinib were consistent with those previously observed. Funding: Eisai Inc. ? 2018 Elsevier Ltd |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85042855944&doi=10.1016%2fS0140-6736%2818%2930207-1&partnerID=40&md5=e8b4243ac34c8dab49ec223962a6b08b https://scholars.lib.ntu.edu.tw/handle/123456789/580076 |
ISSN: | 0140-6736 | DOI: | 10.1016/S0140-6736(18)30207-1 | SDG/關鍵字: | lenvatinib; sorafenib; antineoplastic agent; carbanilamide derivative; lenvatinib; nicotinamide; quinoline derivative; sorafenib; adult; aged; Article; body weight loss; controlled study; decreased appetite; diarrhea; drug withdrawal; female; hand foot syndrome; hazard ratio; hepatic portal vein; human; hypertension; liver cell carcinoma; major clinical study; male; median survival time; multicenter study; overall survival; phase 3 clinical trial; randomized controlled trial; side effect; tumor invasion; analogs and derivatives; clinical trial; comparative study; liver cell carcinoma; liver tumor; middle aged; mortality; survival rate; treatment outcome; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Quinolines; Survival Rate; Treatment Outcome |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。